The Low Affinity IgE Receptor (CD23) Is Cleaved by the Metalloproteinase ADAM10*

Received for publication, August 31, 2006, and in revised form, March 13, 2007. Published, JBC Papers in Press, March 27, 2007, DOI 10.1074/jbc.M608414200

George A. Lemieux**, Fernando Blumenkron*, Nolan Yeung*, Pei Zhou†, Jason Williams**, Amrie C. Grammer*, Robert Petrovich**, Peter E. Lipsky†, Marcia L. Moss**‡, and Zena Werb‡‡

From the †Department of Anatomy and the Biomedical Sciences Program, University of California, San Francisco, California 94143, ‡Cognosci, Research Triangle Park, North Carolina 27710, §Duke University Medical Center, Durham, North Carolina 27710, ‡‡B Cell Biology Group, Autoimmunity Branch, NIAMS, National Institutes of Health, Bethesda, Maryland 20892, **NIEMS, National Institutes of Health, Research Triangle Park, North Carolina 27710, and §§BioZyme Inc., Apex, North Carolina 27523

The low affinity IgE receptor, FcεRII (CD23), is a 46-kDa type II membrane protein that is expressed on B-cells and cells of the myeloid lineage (1). CD23 has multiple functions. It is both a positive and negative regulator of IgE synthesis. The protease activity that converts the membrane-bound form of CD23 into a soluble species (sCD23) is an important regulator of the function of CD23 and may be an important therapeutic target for the control of allergy and inflammation. We have characterized the catalytic activity of ADAM (a disintegrin and metalloproteinase) 10 toward human CD23. We found that ADAM10 efficiently catalyzes the cleavage of peptides derived from two distinct cleavage sites in the CD23 backbone. Tissue inhibitors of metalloproteinases and a specific prodomain-based inhibitor of ADAM10 perturb the release of endogenously produced CD23 from human leukemia cell lines as well as primary cultures of human B-cells. Expression of a mutant metalloproteinase-deficient construct of ADAM10 partially inhibited the production of sCD23. Similarly, small inhibitory RNA knockdown of ADAM10 partially inhibited CD23 release and resulted in the accumulation of the membrane-bound form of CD23 on the cells. ADAM10 contributes to CD23 shedding and thus could be considered a potential therapeutic target for the treatment of allergic disease.

In humans, two isoforms of CD23 that differ by only seven amino acids in the short N-terminal cytoplasmic domain are observed (8). CD23a is expressed only on B-cells. Stimulation of B-cells and cells of the myeloid lineage with interleukin-4 (IL-4)3 induces the expression of CD23b. The C-terminal extracellular domain consists of a globular fold that has homology to the C-type lectin family (9). This globular domain has been shown to contain two distinct binding sites, one for IgE and a second that recognizes CD21 (complement receptor 2) (10, 11). At the cell surface CD23 self-assembles to form homotrimers that have a higher affinity for IgE than the CD23 monomer (12, 13). The self-association is driven by a leucine zipper-like domain (14) that connects the N-terminal cytoplasmic and transmembrane domains to the C-terminal globular domain.

Homotrimeric CD23 molecules exhibit a 15-nm α-helical coiled coil stalk that extends the globular C-terminal domains from the plasma membrane (15). Cleavage in the stalk region by a membrane-associated endoproteolytic activity generates soluble fragments of CD23 (sCD23) that possess apparent molecular masses of 37, 33, and 29 kDa (16). All three of these sCD23 fragments exist as homotrimers (15). Smaller fragments of CD23 (25 and 16 kDa) are known. However, these are thought to be formed from cleavage of the larger soluble fragments by a cysteine protease (16). In vitro sCD23 promotes the differentiation of germinal center B-cells into plasma cells (17), stimulates IgE synthesis in B-cells (18), and induces the secretion of proinflammatory cytokines in monocytes (6, 19, 20). In vivo, inhibition of proteolytic shedding of CD23 using small molecule metalloproteinase inhibitors has been shown to suppress IgE synthesis in Scid mice that have transplanted human peripheral blood lymphocytes (21, 22).

The identities of the protease activities responsible for generating the 33- and 37-kDa forms of CD23 remain elusive. Release of the 33-kDa fragment from the human B-cell line RPMI 8866 has been shown to be mediated by a membrane-associated metalloproteinase activity (23). It has been demonstrated that members of the disintegrin/metalloproteinase fami-

---

* This work was supported by National Institutes of Health Grants A1053194 and HL75602 (to Z. W.), the Sandler Family Sustaining Foundation, and Institutional National Research Service Award HL07731. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

† To whom correspondence may be addressed: Biozyme Inc, Apex, NC 27523. Tel.: 919-362-1399; Fax: 919-362-1399; E-mail: mmoss@biozyme-inc.com.

‡ To whom correspondence may be addressed: Dept. of Anatomy, University of California, San Francisco, CA 94143-0452. Tel.: 415-476-4622; Fax: 415-476-4565; E-mail: zena.werb@ucsf.edu.

‡‡ The abbreviations used are: IL, interleukin; ADAM, a disintegrin and metalloproteinase; TNF, tumor necrosis factor; NIEHS, National Institute of Environmental Health Sciences.
ily (ADAM8, -15, and -28) are capable of cleaving CD23 (24). However, the peptide sequence used to test proteolytic activity was not derived from the known 33- and 37-kDa cleavage sites of CD23 (16). In this paper, we provide evidence that ADAM10 is catalytically competent in cleaving human CD23 at the known physiologic sites and that it sheds CD23 from human cell lines and primary cultures of human B-cells.

EXPERIMENTAL PROCEDURES

Reagents—Commercial reagents were obtained from the following sources: Recombinant human IL-4 and recombinant human catalytic/disintegrin domains of ADAMs 8, 10, and 17 were from R&D Systems (Minneapolis, MN). Tissue inhibitors of metalloproteinase (TIMPs) were from R&D Systems. TAPI-2 was obtained from Calbiochem. Complete proteinase inhibitor mixture was from Roche Applied Science. All other chemicals unless specified otherwise were obtained from Sigma. 2,4-Dinitrophenyl-labeled (DNP) peptides (Table 1) were purchased from Calbiochem (San Diego, CA). Rabbit polyclonal anti-CD23 was from Anaspec (San Jose, CA). Human CD23 ELISA kits were from BD Biosciences and Invitrogen.

PCR and Cloning—A clone of full-length mouse ADAM8 was obtained from the American Type Culture Collection (ATCC, Manassas, VA) and used as a PCR template. The primers 5′-ATGCTCGTTGCAGCTTTGCTGTCAACTCG-3′ (forward) and 5′-AGATCCAAAGTATGTCACACTGCAAGCT-AATATGAGA-3′ (reverse) were used to generate a PCR product that was cloned into a gateway-modified pQCXIP vector. The construct targets the previously described sequence (26). The construct targets the sequence 5′-GACAUUUCAACCACACCAAA-3′. Complementary oligonucleotides encoding the above sequence followed by a hairpin sequence (5′-TTCAGGAGA-3′) and then the reverse complement of the target sequence were annealed and cloned into the retroviral siRNA expression vector pSIREN-retro-Q (Clontech). The negative control construct pSIREN-retro-Qneg is available commercially from Clontech.

Determination of Enzyme Concentration—The substrate dabcyll-LAQhaptopeRSCM(NL-fluorescein)-NH2, 5–10 μM, was added from a 5 mM Me2SO stock into buffer, 20 mM Tris, pH 7.5, and 0.0075% Brij 35. Enzyme (10 μl of a 1/30 diluted stock solution; 200 μg/ml) was added to a 96-well black-coated Costar plate. TIMP1, from a 7.6 mg/ml stock solution, was diluted to 1 μM in the above buffer. It was then serially diluted in 3-fold increments from 1 μM to 3 nM. The diluted TIMP1, 10 μl, was added to the enzyme and allowed to preincubate for 10–15 min after which substrate in buffer (80 μl) was added to initiate the reaction. Reaction progress was monitored continuously in a Cytofluor plate reader by following the change in fluorescence using an excitation of 485 nm and an emission of 530 nm. Data were fit to the Morrison equation to calculate the enzyme concentration (44).

\[ \frac{k_{cat}}{K_m} \] Determination for DNP-Peptide Substrates—The specificity constant \( k_{cat}/K_m (s^{-1} M^{-1}) \) is calculated as \( k_{cat}/K_m = M/(3600 A_e C_e) \), where \( M \) (counts/h) is the slope of the net absorbance versus time curve in the early linear range, \( A_e \) (counts) is the net increase in absorbance reading at reaction end, \( C_e \) (m) is the concentration of enzyme in reaction, and 3600 is a conversion factor (s/h).

Cleavage of DNP-Peptide Substrates—Recombinant ADAM protease (ADAM8, -10, or -17), 5 μM, was diluted into 50 μl of buffer containing 20–100 μM DNP-substrate. The final concentration of enzyme varied from 50 to 500 nM. The reaction progressed at 37 °C for 40–120 min. The reactions were quenched with an equal volume of 1% heptfluorobutyric acid and spun to remove precipitated protein. Reaction products were run on a C18 Vyadac column using solvents containing 0.1% HFBA with an acetonitrile/water gradient. Peaks were detected with a wavelength of 350 nm. Cleavage sites were determined either by liquid chromatography/mass spectro-
ADAM10 Is a CD23 Sheddase

copy (LC/MS; Synpep and Duke University) or by co-chromatography with standard products using two HPLC systems.

Cell Culture—U937 (University of California, San Francisco (UCSF) cell culture core) and Ramos (provided by A. DeFranco, UCSF) cells were cultured in RPMI 1640 supplemented with glutamax (Invitrogen), 10% fetal bovine serum (FBS), and penicillin/streptomycin. HEK293T (ATCC) and GP2–293T (Clontech) were cultured in DME-H21 (UCSF cell culture core) supplemented with 2 mM glutamine and 10% FBS. Peripheral blood mononuclear cells were obtained from healthy adult normal volunteers by centrifugation of leukapheresis fractions over diatrizoate/Ficoll gradients (Sigma) and lysing of red blood cells with ACK buffer (ammonium chloride-potassium chloride; Quality Biological, Gaithersburg, MD). B-cells, purified by negative selection using the Rosette-sеп technique following the manufacturer’s instructions (StemCell Technologies, Vancouver, Canada), were cultured (1 × 10^5 cells/well, 0.5 × 10^6 cells/ml) in 96-well microtiter plates (Costar, Corning Life Sciences, Acton, MA) in RPMI medium (Invitrogen) supplemented with penicillin G (200 units/ml), gentamicin (10 μg/ml), and 5% FBS (200 μl final volume) and incubated at 37 °C in a humidified atmosphere of 5% CO₂.

Retroviral Transduction—Stable cell lines expressing dominant negative ADAM constructs and siRNAs were produced by retroviral transduction using vesicular stomatitis virus type G (VSV-G) enveloped viruses. The viruses were produced using a pantrropic packaging system (Clontech). Retroviral expression vectors (pQCXIP or pSIREN-retro-Q) were co-transfected (FuGENE 6, Roche Applied Science) with a vector encoding the VSV-G envelope protein into GP2-293T packaging cells. 48 h later, U937 cells were suspended in the conditioned medium from the packaging cells that was supplemented with 4 μg/ml Polybrene; 24 h after transduction, stable cells were selected with 2 μg/ml puromycin for 5 days.

CD23 Release from HEK293T Cells—HEK293T cells (250,000/well) were seeded into a 24-well plate and allowed to attach overnight. Using Transfectin (Bio-Rad) cells were co-transfected with plasmids encoding C-terminal HA-tagged CD23b (CD23-HA) and full-length ADAM10, ADAM10(E385A), ADAM8, ADAM17, or empty vector (pQCXIP). The medium was replaced with culture medium containing reduced FBS (1%) 24 h after transfection. The reduced serum supernatant was harvested 24 h later. The conditioned medium was cleared by centrifugation (10,000 × g for 10 min) and supplemented with proteinase inhibitor mixture (Complete). The supernatants were then concentrated 10-fold by centrifugal ultrafiltration (Microcon YM-3, Millipore, Billerica, MA). Cells were washed with cold PBS and then lysed in radiolabeled precipitation assay buffer (140 mM NaCl, 50 mM Tris-HCl, pH 7.5, 10% glycerol, 2 mM EDTA, 1 mM Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, 1 mM phenylmethylsulfonyl fluoride, and Complete proteinase inhibitor mixture). The cell lysate was clarified by centrifugation (16,500 × g for 10 min). Radioimmunoprecipitation assay buffer lysates and concentrated conditioned media were separated by SDS-PAGE (12% acrylamide gels) and transferred onto PVDF membrane for Western blotting using a monoclonal anti-HA antibody (HA.11, Covance); this was followed by secondary detection using a goat anti-mouse IgG-horseradish peroxidase conjugate and chemiluminescence detection using the ECL substrate (Amersham Biosciences).

CD23 Release from U937 and Ramos Cells—Cells (100,000/well) were seeded in round-bottomed 96-well plates (Sarstedt, Newton, NC) in 0.2 ml of medium supplemented with IL-4 and either inhibitors (A10-(23–213) 150–600 nM, GM6001 10–50 μM, TAPI-2 10–50 μM, TIMPs 250 nM) or vehicle controls (A10-(23–213) buffer: 25 mM NaH₂PO₄, pH 7.0, 125 mM KCl, 75 mM NaCl 20% glycerol, PBS, or dimethyl sulfoxide). Cells were cultured for 24 h. The conditioned medium was harvested by centrifugation (2000 × g, 15 min) and assayed by ELISA for soluble CD23 according to the manufacturers’ instructions (BD Biosciences or Invitrogen).

Flow Cytometric Analysis of Primary B-cell Cultures Treated with wtA10-(23–213)—Purified B-cells were cultured for 12 h in the presence or absence of IL-4 (100 ng/ml), wtA10-(23–213) (1–5 μM), or matched diluent control (25 mM Tris-HCl, pH 8, 100 mM NaCl, 10% glycerol, 0.1% β-mercaptoethanol). Cells were stained for expression of surface antigens following washing with 1% bovine serum albumin/PBS. Cells were incubated for 30 min at 4 °C in the dark with fluorochrome-conjugated monoclonal antibodies APC-CD19 (Caltag, Burlingame, CA) or CD23-PE or an isotype-matched control IgG₁-PE (BD Biosciences) before washing to remove unbound antibodies. Cells were resuspended in PBS and immediately analyzed using FACS Calibur (BD Biosciences). The software program Flowjo (TreeStar, Ashland, OR) was used to analyze the data generated by flow cytometry.

Co-immunoprecipitation—HEK293T cells were seeded into 10-cm plates and allowed to adhere overnight. The cells were then co-transfected (Transfectin, Bio-Rad) with expression vectors encoding ADAM10ΔMP-FLAG and CD23-HA or vector controls (pQCXIP or pIRES2eGFP). Forty-eight hours post-transfection the cells were washed twice with PBS (all procedures at 4 °C) and then lysed in co-immunoprecipitation buffer (50 mM Tris-HCl, pH 7.4, 140 mM NaCl, 10 mM CHAPS, 10% glycerol, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, Complete proteinase inhibitor mixture). Lysates were clarified by centrifugation (16,500 × g, 20 min). The total protein concentration of the supernatants was adjusted to 1 mg/ml with lysis buffer. Polyclonal sera (5 μg, Sigma) against either the HA or FLAG epitopes were added to 1 ml of lysate, incubated for 2 h, and then precipitated using protein A-agarose (Invitrogen). The agarose beads were washed with co-immunoprecipitation buffer and then treated with loading buffer, separated by SDS-PAGE, and blotted onto PVDF membranes. The membranes were probed with mouse monoclonal antibodies against the FLAG epitope (M2, Stratagene) or against the HA epitope (HA.11, Covance).

Stimulated CD23 Release—U937 cells that were cultured for 24 h with IL-4 (20 ng/ml) were washed and resuspended in PBS (5 × 10⁶/ml) and A10-(23–213), A10-(23–181), TAPI-2, or vehicle control (A10-(23–213) buffer) was then added. Following the addition of stimulus (ionomycin 1 μM; lysophosphatidic acid 10 μM; sphingosine 1-phosphate, phosphor myristate acetate 100 μM; adenosine triphosphate 0.25 μM; or vehicle controls (Me₂SO, PBS)) cells were incubated at 37 °C for 45 min.
The supernatants harvested following centrifugation (10 min at 1,000 × g) were then assayed for CD23 content by ELISA.

**Time Course for CD23 Shedding**—U937 cells (both vector control and ADAM10 siRNA transduced cells) were cultured with IL-4 overnight. Cells were washed twice with PBS and resuspended at a density of 500,000/ml in fresh growth medium. Cells were incubated at 37 °C for time periods of 1, 3, 5, and 7 h. After each time point, clarified supernatants were obtained by centrifugation (10 min at 1,000 × g) and stored at −80 °C until CD23 levels could be determined by ELISA.

**RESULTS**

In human serum, there are five observed molecular weights of sCD23: 37, 33, 29, 25 and 16 kDa. The cleavage sites that give rise to the 37- and 33-kDa forms of the receptor are known and were used to design N-terminal DNP-labeled peptide substrates. Cleavage of the peptides by recombinant human ADAM10 (rhADAM10) was monitored by HPLC separation of the cleavage products. Substrates were used to design N-terminal DNP-labeled peptide substrates. The substrate DNP-RAEQQLKSKDL was cleaved by rhADAM10 with specificity constants of 190 ± 20 M⁻¹ s⁻¹ and 33-kDa form of sCD23. This substrate was cleaved by rhADAM10 at both the physiological Glu-Gln site and a nonphysiological Glu-Gln site. In contrast, rhADAM8 cleaved the 33-kDa peptide only at the nonphysiological Glu-Gln and Glu-Gln sites. Recombinant human ADAM10, the closest family member of ADAM10, did not possess activity toward either the 37- or 33-kDa peptide but was able to cleave a derived peptide from the cleavage site of TNF-α (data not shown).

To examine the ability of ADAM10 to cleave CD23 in a cell-based assay, we transiently co-transfected ADAM10 and CD23 into HEK293T cells. Wild-type ADAM10 (A10), ADAM10 containing a point mutation (E385A) that renders the proteinase inactive (A10EA), or vector alone was co-transfected with C-terminal HA-tagged CD23 (CD23-HA). After 48 h, the conditioned medium was harvested, and cells were washed and solubilized in radioimmune precipitation assay buffer. Samples from each transfection were separated by SDS-PAGE, transferred to PVDF membranes, and analyzed by Western blotting for soluble and membrane-bound CD23-HA. The top and bottom panels in Fig. 1A show the conditioned medium and cell lysates, respectively, probed with an anti-HA antibody for the presence of CD23-HA. Transfection of A10 enhanced the accumulation of CD23-HA in the supernatant. Both the A10EA and the vector control transfectants exhibited a background level of CD23 shedding that was partially inhibited using the broad spectrum metalloproteinase inhibitor TAPI-2. Quantification of the band intensity in each lane from multiple experiments indicated that transfection with A10 increased shedding by about 50% over vector control transfection (Fig. 1B). In contrast, transfection with the catalytically inactive A10EA did not increase sCD23 production relative to the vector control. Co-transfection of HEK293T cells with ADAM8 (A8) and CD23-HA resulted in a marked increase in sCD23 in the medium (Fig. 1C) as reported previously (24). In contrast, co-transfection of ADAM17 (A17) marginally affected shedding of CD23-HA from these cells.

The expression of endogenous CD23 is positively regulated by IL-4 in many types of leukocytes. However, the effect of IL-4 on ADAM10 expression is unknown. We cultured U937 promonocytic leukemia cells in the presence of IL-4 for 24 h and analyzed the expression of ADAM10 in cell lysates by Western blotting (Fig. 2, top panel). IL-4 slightly increased the amount of ADAM10 present in the lysates. However, it was a much stronger positive regulator of CD23 (Fig. 2, middle panel). Increases in sCD23 upon exposure to IL-4 are more

**TABLE 1**

| Protein | Peptide | \(k_{cat}/K_m\) M⁻¹ s⁻¹ |
|---------|---------|-------------------------|
| APP     | DNP-EVHdqKLvfae | 350 ± 150              |
| CD23    | DNP-RAEQQLKskdl | 190 ± 20               |
| 33kDa   | DNP-HGdqMAqksqst | 90 ± 10               |
| CD23    | DNP-HGdqMAqksqst | 250 ± 100             |
| 37kDa   | DNP-GLPENLKQGTD | <5                     |

**TABLE 2**

| Protein | Peptide | Phys? | 37 kDa | Phys? |
|---------|---------|-------|--------|-------|
| ADAM    | 33 kDa  | No    | QMA    | QKS   |
| 8       | AEQ    | No    | QRL    | QQRL  |
| 10      | QQR    | Yes   | QMA    | QKS   |
| 17      | Not cleaved | Not cleaved |        |       |

**ADAM10 Is a CD23 Sheddase**

The "Phys" column indicates physiological (Yes) or nonphysiological (No) site, and "indicates cleavage site.
ADAM10 Is a CD23 Sheddase

The recombinant prodomain of ADAM10 (amino acids-(23–213), wtA10-(23–213)) is a potent, selective inhibitor (Ki = 48 nM) of ADAM10 in vitro and in cell culture. Mutation of the cysteine switch region (C173S) improves the stability of the reagent and maintains the potency (Ki = 36 nM) and selectivity toward ADAM10. At concentrations of 600 and 300 nM the C173S mutant (A10-(23–213)) inhibited shedding of CD23 from U937 cells by about 30% and from Ramos cells by about 20% (Fig. 3, A and B). At lower concentrations the inhibitory activity diminished in this cellular assay of CD23 shedding. A truncated prodomain (A10-(23–181)), based on the full-length Cys-to-Ser mutant of ADAM10, was a poor inhibitor of the metalloproteinase in vitro (Ki = >5 μM) and weakly inhibited sCD23 production (Fig. 3, A and B).

Primary cultures of peripheral blood B-cells isolated from normal healthy adults were treated either with wtA10-(23–213) or vehicle control and cultured with or without IL-4 for 12 h at 37 °C. The cultures were then stained with fluorochrome-labeled anti-CD19 and anti-CD23 and analyzed by flow cytometry. In the absence of IL-4, treatment of the cultures with wtA10-(23–213) induced a shift in the percentage of CD23/CD19 double-positive cells from 38% in the diluent control sample to 56% in the wtA10-(23–213)-treated sample (Fig. 3C). Conversely, the percentage of CD19-positive, CD23-negative cells decreased from 53% in the diluent control sample to 36% in the wtA10-(23–213)-treated sample. Treatment with proteolytically inactive A10-(23–181) did not affect the percentage of positive cells (data not shown). The density (determined by mean fluorescence intensity) of CD23 on the double-positive cells was found to be insensitive to the presence of wtA10-(23–213). IL-4-treated cells responded differently to wtA10-(23–213) in that treatment with wtA10-(23–213) did not affect the percentage of CD23/CD19 double-positive cells in the sample, but it increased the density of CD23 present on the CD23/CD19 double-positive cells (Fig. 3D). The IL-4-stimulated, wtA10-(23–213)-treated CD19+ cells exhibited 2.5-fold greater mean density of cell surface CD23 than the vehicle control-treated cells. Prolonged treatment of IL-4-stimulated cells (36 h) with wtADAM10-(23–213) increased the percentage of cells that were CD23-positive from 83% in the diluent control to 98% in the inhibitor-treated sample (data not shown).

The ADAM family of proteinases is also involved in the shedding of cell surface proteins that is stimulated by various small molecule agonists. Cells cultured overnight with IL-4 were
Mutant versions of ADAM proteins that lack metalloproteinase domains have been shown to function as dominant-negative alleles that suppress shedding of proteinase substrates (26–28). We examined the effect of metalloproteinase-deleted alleles of ADAM8 (A8) and ADAM10 (A10) on the shedding of CD23 from U937 cells. The mutant alleles were cloned into a retroviral expression vector (pQCXIP) and transduced into U937 cells by retroviral delivery. Puromycin-resistant cells were then stimulated with IL-4 overnight, and the conditioned medium was assayed for the presence of sCD23 (Fig. 5A). Both A8ΔMP and A10ΔMP exhibited significantly reduced (20–25%) production of sCD23 compared with the vector control cells. The A17ΔMP-transduced cells produced amounts of sCD23 similar to vector control cells. These results are consistent with both ADAM8 and ADAM10 being CD23 sheddases and with ADAM17 having no activity toward this protein.

We also found that A10ΔMP physically associated with CD23 (Fig. 5B). A C-terminal FLAG-tagged ADAM10 construct (A10ΔMP-FLAG) was co-transfected with CD23-HA into HEK293T cells. The transfected cells were cultured for 48 h and then washed with PBS and lysed in co-immunoprecipitation buffer. The extracts were then cleared by centrifugation, and the supernatants were immunoprecipitated with monoclonal sera against the respective epitope tags. The precipitated complexes were separated by SDS-PAGE and transferred to PVDF membranes. When CD23-HA and A10ΔMP-FLAG were co-transfected, immunoprecipitation of CD23-HA resulted in the co-precipitation of A10ΔMP (Fig. 5B, top left panel). In the absence of transfected CD23-HA, A10ΔMP-FLAG was not detectable following precipitation. In both lysates A10ΔMP-FLAG was expressed, although A10ΔMP-FLAG expression levels were considerably higher in the absence of CD23-HA (Fig. 5B, lower left panel). Immunoprecipitation of A10ΔMP-FLAG resulted in the co-precipitation of CD23-HA in co-transfected cells (Fig. 5B, upper right panel). In the absence of transfected A10ΔMP-FLAG, a residual amount of CD23-HA still precipitated. The expression level of CD23-HA was similar in both lysates.

Endogenous ADAM10 in U937 cells was depleted using RNA interference. A construct encoding a hairpin siRNA specific for human ADAM10 (29) was cloned into a retroviral RNA interference vector and transduced into U937 cells along with a control siRNA. The stably transduced cells exhibited ADAM10 protein levels that were depleted ~50% compared with the control cells (Fig. 6A). Overnight stimulation of these cells with IL-4 followed by assay of the conditioned media using a CD23

**FIGURE 3.** CD23 release is inhibited in both human leukemia cell lines and primary human B-cell cultures by metalloproteinase inhibitors. A, U937 cells were cultured with IL-4 (20 ng/ml) and in the presence of broad spectrum metalloproteinase inhibitors TAPI-2 and GM6001 (20 μM), recombinant TIMPs 1–3 (250 μM), a potent specific ADAM10 inhibitor (A10-(23–213); 150, 300, and 600 nM) or a weak ADAM10 inhibitor (A10-(23–181); 600 nM). After 24 h the conditioned medium was harvested, and soluble CD23 was assayed by ELISA. B, Ramos cells treated as described in A. In A and B, data are the mean ± S.E. of three independent experiments C, primary peripheral blood B-cells were cultured with wtA10-(23–213) (5 μM, black line) or vehicle control (gray line) for 12 h and stained with APC-anti-CD19, anti-CD23-PE, or isotype-matched control antibody (dotted line). Data represent CD23 expression by CD19+ B-cells. D, primary peripheral blood B-cells were cultured with IL-4 (50 ng/ml) and either wtA10-(23–213) (1 μM, black line) or vehicle control (gray line) for 12 h. Cells were stained with APC-anti-CD19, anti-CD23-PE, or isotype-matched control antibody (dotted line). Data represent CD23 expression by CD19+ B-cells.

**FIGURE 4.** Stimulated shedding of CD23 in U937 cells is inhibited by metalloproteinase inhibitors. A, sCD23 was quantified in supernatants by ELISA from IL-4-stimulated U937 cells that were treated for 45 min at 37 °C with no stimulus, ATP (0.2 mM), ionomycin (1 μM), sphingosine 1-phosphate (5-1-P, 1 μM), LPA (10 μM), or PMA (100 nM). B, inhibition of stimulated CD23 shedding assayed as described in A by A10-(23–213) (500 nM) and TAPI-2 (20 μM). Data are the mean ± S.D. in both A and B.

washed and treated with various agonists for 45 min at 37 °C. After centrifugation, the sCD23 in the cleared supernatants was determined by ELISA (Fig. 4A). Both PMA and lysophosphatidic acid (LPA) strongly induced shedding. Other reported agonists of shedding such as ATP and ionomycin only weakly induced shedding of CD23 from U937 cells. Sphingosine 1-phosphate did not stimulate shedding. Both A10-(23–213) and TAPI-2 were used to evaluate the contribution of ADAM10, and of metalloproteinases in general, to the stimulated shedding of CD23 (Fig. 4B). The weakly induced shedding by ATP and ionomycin was inhibited slightly more so by A10-(23–213) than the unstimulated control, whereas inhibition by TAPI-2 was relatively constant. In the samples strongly stimulated by LPA and PMA, A10-(23–213) was a poorer inhibitor of CD23 release than in the unstimulated control. Although TAPI-2 inhibited PMA-induced shedding in a manner comparable with the unstimulated control, it was a somewhat weaker inhibitor of LPA-induced shedding.

Mutant versions of ADAM proteins that lack metalloproteinase domains have been shown to function as dominant-negative alleles that suppress shedding of proteinase substrates (26–28). We examined the effect of metalloproteinase-deleted alleles of ADAM8 (A8ΔMP), ADAM10 (A10ΔMP), and ADAM17 (A17ΔMP) on the shedding of CD23 from U937 cells. The mutant alleles were cloned into a retroviral expression vector (pQCXIP) and transduced into U937 cells by retroviral delivery. Puromycin-resistant cells were then stimulated with IL-4 overnight, and the conditioned medium was assayed for the presence of sCD23 (Fig. 5A). Both A8ΔMP and A10ΔMP exhibited significantly reduced (20–25%) production of sCD23 compared with the vector control cells. The A17ΔMP-transduced cells produced amounts of sCD23 similar to vector control cells. These results are consistent with both ADAM8 and ADAM10 being CD23 sheddases and with ADAM17 having no activity toward this protein.

We also found that A10ΔMP physically associated with CD23 (Fig. 5B). A C-terminal FLAG-tagged ADAM10 construct (A10ΔMP-FLAG) was co-transfected with CD23-HA into HEK293T cells. The transfected cells were cultured for 48 h and then washed with PBS and lysed in co-immunoprecipitation buffer. The extracts were then cleared by centrifugation, and the supernatants were immunoprecipitated using polyclonal sera against the respective epitope tags. The precipitated complexes were separated by SDS-PAGE and transferred to PVDF membranes. When CD23-HA and A10ΔMP-FLAG were co-transfected, immunoprecipitation of CD23-HA resulted in the co-precipitation of A10ΔMP (Fig. 5B, top left panel). In the absence of transfected CD23-HA, A10ΔMP-FLAG was not detectable following precipitation. In both lysates A10ΔMP-FLAG was expressed, although A10ΔMP-FLAG expression levels were considerably higher in the absence of CD23-HA (Fig. 5B, lower left panel). Immunoprecipitation of A10ΔMP-FLAG resulted in the co-precipitation of CD23-HA in co-transfected cells (Fig. 5B, upper right panel). In the absence of transfected A10ΔMP-FLAG, a residual amount of CD23-HA still precipitated. The expression level of CD23-HA was similar in both lysates.
ELISA revealed that the amount of CD23 produced was reduced by 35% in the conditioned medium from the ADAM10 siRNA-treated cells versus the control cells (Fig. 6B). Both the ADAM10 siRNA cells and the control cells were cultured with and without IL-4 and/or TAPI-2 for 24 h. The concentrated conditioned medium and whole cell lysates were separated by SDS-PAGE and transferred to PVDF membrane for Western blotting with CD23 antiserum (Fig. 6C, top two panels) or actin antiserum (loading control; Fig. 6C, bottom panel). In the absence of IL-4, very little CD23 was present in either the conditioned medium and in the cell lysate. In the presence of IL-4, CD23 was induced in both the conditioned medium and in the cell lysate. In the conditioned medium the CD23 appeared to migrate with an apparent molecular mass of 37 kDa. In the cell lysate, CD23 appeared to migrate at 45 kDa. The accumulation of the 37-kDa form of CD23 in the conditioned medium was inhibited using the broad spectrum metalloproteinase inhibitor TAPI-2. Conversely, treatment of IL-4-stimulated cells with TAPI-2 led to an increase in the amount of the higher molecular mass form of CD23 associated with the cells. Compared with the control cells, ADAM10-depleted cells produced less of the 37-kDa soluble form of CD23 than the control cells. However, the ADAM10-depleted cells possessed more of the cell-associated 45-kDa form of CD23 than the wild-type cells. Quantification of the blots revealed that the ratio of sCD23 to mCD23 in the ADAM10-depleted cells was 0.4, and that of the control cells was 1.4.

We also assessed the rate of release of soluble CD23 from ADAM10-depleted versus wild-type cells. Cells were stimulated for 24 h and then washed with medium, resuspended in fresh medium, and incubated at 37 °C s for 1–7 h. The conditioned medium at each time point was then used to assay soluble
CD23 production by ELISA. A plot of CD23 concentration in the conditioned medium versus time shows that the rate of sCD23 production is lower in the ADAM10-depleted cells than in the control cells (Fig. 6D). The control cells produced CD23 at a rate of 0.19 ± 0.04 ng·ml⁻¹·h⁻¹. In contrast, the ADAM10-depleted cells released soluble CD23 at a rate of 0.11 ± 0.02 ng·ml⁻¹·h⁻¹, and TAPI-2-treated control cells released sCD23 at a rate of 0.02 ± 0.01 ng·ml⁻¹·h⁻¹.

**DISCUSSION**

Proteolytic shedding of membrane proteins is an evolutionarily conserved post-translational modification that regulates the physiological activity of numerous proteins (30). The ADAM family of disintegrin/metalloproteinases has been shown to catalyze many of these cell surface endoproteolytic events. The cellular and physiological processes that are directly regulated by ADAMs include growth factor activation, chemokine mobilization, cell fate specification, and cell adhesion (31–33). Release of the 33-kDa sCD23 fragment from the human B-cell line RPMI 8866 has been shown to be mediated by membrane-associated metalloproteinase activity (23). ADAM8 has been shown capable of cleaving CD23 when co-transfected in HEK293 cells (24). However, the peptide sequence used to test activity of ADAM8 on CD23 was not derived from the known 33- and 37-kDa cleavage sites of CD23 (16). Despite the potential role of sCD23 in allergic and inflammatory diseases, the identity of the proteinase activities responsible for generating sCD23 remains elusive.

We investigated shedding of CD23 in human cells because the functional significance of mouse sCD23 is unclear. Serum IgE levels are elevated in CD23 knock-out mice indicating that CD23 is a negative regulator of IgE in vivo (34). However, transgenic mice that over-express mouse sCD23 exhibit no apparent IgE phenotype (35). Several biochemical differences between human and mouse CD23 may explain this disparity. Mouse CD23 is 55% identical to human CD23 at the amino acid level. The location and identity of the cleavage sites of mouse sCD23 are not conserved in human CD23 (36). Human sCD23 stimulates IgE synthesis in vitro through binding CD21 (18). Recent structural data predict that mouse sCD23 lacks a CD21 binding site (10). In addition, mouse sCD23 binds to IgE with an affinity that is >10-fold weaker than human CD23-IgE interaction (36). Because of these disparities, mice may not be adequate models for the function of sCD23 in IgE homeostasis.

Identification of the cellular protease that cleaves a particular substrate is facilitated when the physiological cleavage site of that substrate is known. The peptide cleavage data indicate that the ADAM10 catalytic domain possesses the catalytic capability to cleave CD23 directly at sites that are known to be physiologically relevant. There is evidence that cleavage of protein substrates by ADAMs likely involves ADAM-substrate interactions outside of the catalytic domain (37). We have demonstrated that a metalloproteinase-deficient mutant of ADAM10 co-immunoprecipitates with CD23, suggesting that ADAM10 and CD23 are present within the same complex in the cell. Thus, there is strong support for a direct action of ADAM10 on CD23.

Cell-based assays support the cellular role of ADAM10 in shedding CD23. Although overexpression of ADAM10 enhanced shedding of CD23, inhibition of ADAM10 function through either the use of specific inhibitors, dominant-negative ADAM10 constructs, or depleting ADAM10 by siRNA led to a reduction in CD23 shedding. However, depletion of cellular ADAM10 was not complete in cells transduced with the ADAM10 siRNA. Because targeted interference with ADAM10 function did not reduce CD23 shedding as much as the use of the broad spectrum metalloproteinase inhibitor TAPI-2, inhibition of its activity may have been incomplete. Shedding of integral membrane proteins may take place within intracellular compartments as well as at the cell surface (38). Although ADAM10-(23–213) is a potent, specific ADAM10 inhibitor in vitro, its polypeptide composition may render it cell-impermeable and thus may not efficiently inhibit ADAM10 in a cell-based assay. The residual ADAM10 activity may account, at least part, for the remaining CD23 sheddase activity in these cells.

A second reason for the failure of targeted inhibition of ADAM10 to inhibit CD23 shedding completely in the cell-based assays may be the presence of other proteinases that are functionally redundant with ADAM10. This phenomenon has been observed for other ADAMs substrates (39). For example, utilizing both cell-based assays and peptide cleavage assays, it has been demonstrated that the amyloid precursor protein, APP, can be cleaved by ADAM8, ADAM9, ADAM10, and ADAM17 (40). Mouse embryonic fibroblasts from Adam10⁻/⁻ mice process APP normally (41). However, the phenotypes resulting from the overexpression of ADAM10 as well as dominant-negative ADAM10 in a mouse model of Alzheimer disease are consistent with ADAM10 being a physiological APP sheddase (42). Stimulated shedding of CD23 from U937 cells by different small molecule agonists was characterized CD23 sheddases. The fact that CD23 is processed physiologically at several sites, and that several ADAMs are expressed in the cell types that express CD23, makes it probable that CD23 shedding is a process controlled by several enzyme activities.

In summary, we have shown that ADAM10 is a physiological CD23 sheddase. The targeted inhibition of ADAM10 in vivo may induce the accumulation of mCD23 and reduce levels of sCD23. Because mCD23 inhibits IgE synthesis and sCD23 stimulates IgE synthesis, alteration of the proteolytic balance between mCD23 and sCD23 through targeted inhibition of ADAM10 may prove to be an important therapeutic intervention point for controlling allergic disease.

**Addendum**—While this manuscript was under review, an article was published (45) that found ADAM10 to be the major CD23 sheddase activity in mice.

**REFERENCES**

1. Delespesse, G., Sarfati, M., Wu, C. Y., Fournier, S., and Letellier, M. (1992) *Immunol. Rev.* 125, 77–97
ADAM10 Is a CD23 Sheddase

2. Gould, H. J., Sutton, B. J., Beavil, A. J., Beavil, R. L., McClloskey, N., Coker, H. A., Fear, D., and Smurthwaite, L. (2003) *Ann. Rev. Immunol.* **21**, 579–628

3. van der Heijden, F. L., Joost van Neerven, R. J., van Katwijk, M., Bos, J. D., and Kapsenberg, M. L. (1993) *J. Immunol.* **150**, 3643–3650

4. Santamaria, L. F., Bheekha, R., van Reijsen, F. C., Perez Soler, M. T., Suter, M., Bruijnzeel-Koomen, C. A., and Muddle, G. C. (1993) *Hum. Immunol.* **37**, 23–30

5. Lecoanet-Henchoz, S., Plater-Zyberk, C., Graber, P., Gretener, D., Aubry, J. P., Conrad, D. H., and Bonnefoy, J. Y. (1997) *Eur. J. Immunol.* **27**, 2290–2294

6. Rezzonico, R., Imbert, V., Chicheportiche, R., and Dayer, J. M. (2001) *Blood* **97**, 2923–2940

7. Lecoanet-Henchoz, S., Gauchat, J. F., Aubry, J. P., Graber, P., Life, P., Paul-Eugène, N., Ferria, B., Corbi, A. L., Dugas, B., Plater-Zyberk, C., and Bonnefoy, J. Y. (1995) *Immunology* **8**, 119–125

8. Yokota, A., Kikutani, H., Tanaka, T., Sato, R., Barsumann, E. L., Suemura, M., and Kishimoto, T. (1988) *Cell* **55**, 611–618

9. Bonnefoy, J. Y., Lecoanet-Henchoz, S., Gauchat, J. F., Graber, P., Aubry, J. P., Jeannin, P., and Plater-Zyberk, C. (1997) *Int. Rev. Immunol.* **16**, 113–128

10. Hibbert, R. G., Teriete, P., Grundy, G. J., Beavil, R. L., Reljic, R., Holers, V. M., Hannan, J. P., Sutton, B. J., Gould, H. J., and McDonnell, J. M. (2005) *J. Exp. Med.* **202**, 751–760

11. Mossalayi, M. D., Arock, M., Delespesse, G., Hofstetter, H., Bettler, B., Dalloul, A. H., Kilchherr, E., Quaaz, F., Debre, P., and Sarfati, M. (1992) *EMBO J.* **11**, 4323–4328

12. Dierks, S. E., Bartlett, W. C., Edmeades, R. L., Gould, H. J., Rao, M., and Conrad, D. H. (1993) *J. Immunol.* **150**, 2372–2382

13. Kilmon, M. A., Ghirlando, R., Strub, M. P., Beavil, R. L., McCloskey, N., Coker, H. A., Fear, D., and Smurthwaite, L. (2003) *Eur. J. Immunol.* **33**, 2615–2624

14. Aubry, J. P., Pochn, S., Graber, P., Hansen, M. J., Khademkar, S., Appelbaum, E., Faller, A., and Marshall, L. A. (2000) *Clin. Exp. Allergy* **30**, 719–727

15. Marolewski, A. E., Buckle, D. R., Christie, G., Earnshaw, D. L., Flamberg, P. L., Marshall, L. A., Smith, D. G., and Mayer, R. J. (1998) *Biochem. J.* **333**, 573–579

16. Letellier, M., Sarfati, M., and Delespesse, G. (1989)

17. Liu, Y. J., Cairns, J. A., Holder, M. J., Abbot, S. D., Jansen, K. U., Bonnefoy, J. Y., Conrad, D. H., and Bonnefoy, J. Y. (1995) *Nature* **379**, 573–576

18. Texido, G., Ebel, H., Le Gros, G., and van der Putten, H. (1994) *J. Immunol.* **153**, 3028–3042

19. Bartlett, W. C., Kelly, A. E., Johnson, C. M., and Conrad, D. H. (1995) *J. Immunol.* **154**, 4240–4246

20. White, J. M. (2003) *Curr. Opin. Cell Biol.* **15**, 598–606

21. Skovronsky, D. M., Moore, D. B., Milla, M. E., Doms, R. W., and Lee, V. M. (2003) *J. Immunol.* **170**, 3139–3145

22. Huovila, A. P., Turner, A. J., Pelto-Huikko, M., Karkkainen, I., and Ortiz, R. M. (2005) *Trends Biochem. Sci.* **30**, 413–422

23. Allinson, T. M., Parkinson, E. T., Turner, A. J., Pelto-Huikko, M., Karkkainen, I., and Ortiz, R. M. (2005) *Trends Biochem. Sci.* **30**, 413–422

24. Bartlett, W. C., Kelly, A. E., Johnson, C. M., and Conrad, D. H. (1995) *J. Immunol.* **154**, 4240–4246

25. White, J. M. (2003) *Curr. Opin. Cell Biol.* **15**, 598–606

26. Skovronsky, D. M., Moore, D. B., Milla, M. E., Doms, R. W., and Lee, V. M. (2003) *J. Biol. Chem.* **278**, 47929–47938

27. Maretzky, T., Reiss, K., Ludwig, A., Buchholz, J., Scholz, F., Proksch, E., de Strooper, B., Hartmann, D., and Saftig, P. (2005) *Proc. Natl. Acad. Sci. U. S. A.* **102**, 9182–9187

28. Blobel, C. P. (2000) *Curr. Opin. Cell Biol.* **12**, 606–612

29. Becherer, J. D., and Blobel, C. P. (2003) *Curr. Top. Dev. Biol.* **54**, 101–123

30. Seals, D. F., and Courtneidge, S. A. (2003) *Trends Biochem. Sci.* **28**, 753–757